Every 8-K that REVIVA PHARMA HLDGS INC (RVPH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RVPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RVPH filings page.
Reviva Pharmaceuticals Holdings, Inc. reported second quarter 2026 results and outlined key milestones for its lead drug candidate brilaroxazine. A U.S. composition of matter patent application for a new form of brilaroxazine is seeking accelerated review, which the company believes could extend patent life and commercial exclusivity through 2046. FDA feedback on use of the new formulation in the RECOVER-2 registrational Phase 3 schizophrenia trial and in a planned New Drug Application is expected in the fourth quarter of 2026, with a bioequivalence study planned for the same period and RECOVER-2 patient enrollment targeted for the first half of 2027, subject to additional financing.
Cash and cash equivalents were $19.9 million as of June 30, 2026, up from $14.4 million at December 31, 2025, with total assets of $21.1 million and total liabilities of $5.9 million. For the quarter, operating expenses fell to $2.6 million from $6.1 million a year earlier, and net loss narrowed to $2.45 million (or $0.19 per share) from $6.05 million (or $2.40 per share). Stockholders’ equity increased to $15.2 million, while accumulated deficit reached $189.8 million. The company’s common stock now trades on the OTCQB Venture Market under the symbol RVPH.
Reviva Pharmaceuticals Holdings, Inc. reported a first quarter 2026 net loss of $3,195,987, about half the $6,432,840 loss a year earlier, as operating expenses fell to $3,271,952 from $6,538,167. Net loss per share narrowed to $0.46 from $2.61, reflecting both lower spending and higher share count.
Cash and cash equivalents rose to $22,190,231 as of March 31, 2026, up from $14,438,792 at year-end, driving total stockholders’ equity to $17,440,481. The company continues to invest in its late-stage CNS pipeline, led by brilaroxazine.
Reviva filed a composition of matter provisional patent application for a new form of brilaroxazine intended to extend commercial exclusivity through 2046. It expects FDA feedback on using this new form in the RECOVER-2 registrational Phase 3 schizophrenia trial and future NDA in mid-2026, with patient enrollment in RECOVER-2 targeted to begin in Q3 2026. Trading of Reviva’s common stock on Nasdaq will be suspended on May 14, 2026, and the shares will be quoted on the OTCQB Venture Market under the symbol RVPH.
Reviva Pharmaceuticals Holdings, Inc. reports that its common stock will be delisted from the Nasdaq Capital Market after failing to meet Nasdaq’s minimum bid price requirement of $1.00 per share under Listing Rule 5550(a)(2) by May 11, 2026.
The Nasdaq Hearings Panel notified the company on May 12, 2026 that trading on Nasdaq will be suspended as of the open on May 14, 2026. On the same date, the stock is expected to begin trading on the OTCQB Venture Market under the existing symbol “RVPH.”
The company adds new risk disclosures explaining that the Nasdaq delisting and OTCQB trading may reduce liquidity and market price, limit access to capital and equity incentives, subject the stock to “penny stock” rules, and increase volatility and difficulty for investors seeking to resell shares.
Reviva Pharmaceuticals Holdings provided shareholders with an update on its lead drug brilaroxazine and its financial position. The company is pursuing a new composition of matter patent on a revised form of brilaroxazine, aiming to extend potential commercial exclusivity, possibly through 2046, and plans to seek FDA alignment to use this new form in a second Phase 3 schizophrenia trial, RECOVER-2.
Reviva expects to start RECOVER-2 trial activities in Q2 2026, begin U.S. patient enrollment in Q3 2026, and complete the study in Q4 2027. The company also highlighted a recent $10 million financing, giving it about $23 million in cash and cash equivalents and an estimated cash runway into Q1 2027, while emphasizing that its business is heavily dependent on successful development and approval of brilaroxazine.
Reviva Pharmaceuticals Holdings, Inc. reported full year 2025 results, highlighting progress toward late-stage development of brilaroxazine for schizophrenia. The FDA recommended a second Phase 3 trial, and Reviva plans to start the RECOVER-2 registrational study in mid-2026 as part of a future NDA package.
For 2025, Reviva posted a net loss of $19.9 million, improving from a $29.9 million net loss in 2024 as total operating expenses fell to $20.2 million from $30.8 million. Research and development expenses declined to $11.7 million, while general and administrative costs rose modestly to $8.5 million.
Cash and cash equivalents were $14.4 million as of December 31, 2025, slightly above the prior year. Stockholders’ equity increased to $8.6 million, supported by higher additional paid-in capital and a larger share count, with 5,872,865 common shares issued and outstanding at year-end.
Reviva Pharmaceuticals Holdings, Inc. has entered into agreements for a registered public offering raising aggregate gross proceeds of $10.0 million. The company will sell 6,283,334 shares of common stock and pre-funded warrants for up to 383,333 shares, together with Series G and Series H warrants exercisable for up to 6,666,667 shares each at an exercise price of $1.50 per share. Net proceeds are expected to be approximately $9.0 million, which Reviva plans to use, along with existing cash, to fund research and development, including its planned RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia, and for working capital and general corporate purposes. The warrants are immediately exercisable, with Series G expiring in five years and Series H in one year, and include beneficial ownership limits of 4.99% or 9.99%.
Reviva Pharmaceuticals Holdings approved a one-for-twenty reverse stock split of its common stock, effective at 12:01 a.m. Eastern Time on March 9, 2026. Every 20 existing shares will convert into 1 share, with no fractional shares issued; holdings will be rounded up to the next whole share.
The par value and authorized share count will not change, but outstanding options and warrants will be adjusted for the new ratio. Reviva is using the reverse split as a key step to regain compliance with Nasdaq’s $1.00 minimum bid price requirement after receiving a delisting notice and a compliance extension through March 27, 2026.
The company warns that the reverse split announcement and implementation could pressure the stock price, reduce trading liquidity due to fewer outstanding shares, and that failure to meet Nasdaq’s listing standards could lead to delisting, harming liquidity, market value, and capital-raising ability.
Reviva Pharmaceuticals Holdings, Inc. reports that a Nasdaq Hearings Panel has granted the company an exception to regain compliance with Nasdaq’s $1.00 minimum bid price requirement for continued listing through March 27, 2026. This gives the company more time to bring its share price back above the required level.
The company adds a new risk factor explaining that it may implement a reverse stock split to help meet the bid price rule and that such a split could negatively affect its share price and trading liquidity. Reviva warns that failure to regain or maintain compliance with Nasdaq listing standards could lead to delisting, which could hurt the stock’s liquidity, price, and the company’s ability to raise capital or pursue business opportunities.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) furnished an 8-K announcing it issued a press release with financial information and operating metrics for the fiscal quarter ended September 30, 2025, and discussed its business outlook.
The materials were furnished under Items 2.02 and 7.01 and are not deemed “filed” for liability purposes. The press release is included as Exhibit 99.1.
Reviva Pharmaceuticals Holdings (RVPH) reported that Nasdaq confirmed the company has regained compliance with the minimum Market Value of Listed Securities requirement. Nasdaq determined RVPH’s MVLS was $35 million or greater for 10 consecutive business days from September 30, 2025 to October 13, 2025, closing that matter.
The company remains out of compliance with Nasdaq’s $1.00 minimum bid price rule, with an initial 180‑day window to regain compliance until November 10, 2025. Reviva said it will continue monitoring its share price and may consider actions, including a potential reverse stock split, noting there is no assurance it will regain or maintain compliance.
Reviva Pharmaceuticals Holdings, Inc. amended its Bylaws on September 26, 2025 to lower the quorum for stockholder meetings from a majority of voting power to one-third (33 1/3%) of the voting power outstanding and entitled to vote, as present in person, by remote communication, or by proxy, except where a higher quorum is required by law or the certificate of incorporation or bylaws. The amendment was approved by the Board and the full text is filed as Exhibit 3.1.
Reviva Pharmaceuticals Holdings, Inc. filed a Current Report disclosing that on September 18, 2025 it launched and priced an offering of securities and entered into a Placement Agency Agreement with A.G.P./Alliance Global Partners to market the offering. The company agreed to pay the placement agent a cash fee equal to 7.0% of aggregate gross proceeds (with a 3.5% fee for proceeds from certain investors as mutually agreed) and to reimburse up to $15,000 for non-accountable expenses and up to $75,000 for out-of-pocket accountable legal expenses. The filing references executed forms of Series E and Series F warrants, a securities purchase agreement, the placement agency agreement, legal opinion of Lowenstein Sandler LLP, and press releases announcing the launch and pricing of the offering as exhibits.
The report includes a forward-looking statement caution noting risks to closing the offering and to anticipated proceeds; the filing does not state the final offering size or the exact proceeds expected in this Current Report text.
Reviva Pharmaceuticals Holdings, Inc. furnished a Current Report on Form 8-K stating it issued a press release on August 14, 2025 that discloses financial information and operating metrics for the fiscal quarter ended June 30, 2025 and discusses business outlook. The filing indicates the press release is attached as Exhibit 99.1 and is incorporated by reference into the report. The company also states the information is being furnished to the SEC and expressly is not being "filed" for purposes of Exchange Act Section 18, limiting the legal liabilities associated with formal filed disclosures.
Reviva Pharmaceuticals (Nasdaq: RVPH) entered into a $10 million registered public offering of 20 million common shares paired with 20 million five-year Series C warrants and 20 million one-year Series D warrants, all priced at $0.50 per unit.
Net proceeds of roughly $9 million will fund R&D, working capital and general corporate purposes. The warrants are immediately exercisable at $0.50, include 4.99%/9.99% ownership caps and Black-Scholes cash-out rights on fundamental transactions. Closing is expected 27 Jun 2025, subject to customary conditions, and the company agreed to 60-day lock-up on most new issuances and a 12-month restriction on variable-rate financings.
- Placement Agent: A.G.P./Alliance Global Partners—7% cash fee on most proceeds.
- Registration: effective S-3 (No. 333-276848), prospectus supplement filed.
- Use of proceeds focused on pipeline advancement.